Cite
HARVARD Citation
Yu, Y. et al. (n.d.). 317OAssociation of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials. Annals of oncology. p. . [Online].